ADMA Biologics
Tracked across 9 events · 640 articles · First seen Apr 01, 2026 · Last active Aug 12, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: ADMA Biologics is the primary subject of the class action lawsuits and investigations due to allegations of channel stuffing, undisclosed related-party transactions, and misleading revenue growth, which caused its stock price to decline significantly.
Apr 01, 2026 · 301 articles
Business
Impact: ADMA Biologics received an $8 million strategic investment and formed a joint venture with Guangzhou-Israel Biotechnology Fund to advance its oncology pipeline in China, accelerating development of BND-67 and BND-22.
Jun 01, 2026 · 7 articles
Business
Impact: ADMA Biologics has been recognized on the CDP Supplier Engagement Assessment A List for the second consecutive year, demonstrating its leadership in engaging suppliers on climate-related issues and strong sustainability performance. This enhances its reputation and attractiveness to ESG-focused investors.
Jun 02, 2026 · 6 articles
Business
Impact: ADMA Biologics is the subject of the event; it retained its MSCI AAA ESG rating and was included in the MSCI Selection Indexes for the fourth consecutive year, reinforcing its sustainability leadership.
Jul 08, 2026 · 6 articles
Regulatory
A securities class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) and certain of its executives, alleging violations of federal securities laws during the Class Period from August 9, 2024 to March…
Impact: ADMA Biologics is the defendant in the securities class action, accused of making false and misleading statements. The lawsuit and allegations have led to a significant drop in its stock price and could result in substantial financial penalties and reputational harm.
Jun 14, 2026 · 294 articles
Business
Impact: ADMA Biologics was selected by Teikoku Seiyaku to provide microbial contract development and manufacturing services for KTP-001, enhancing its position as a global CDMO.
May 26, 2026 · 6 articles
Business
Dark Horse Consulting Group (DHCG), a life sciences consulting firm specializing in advanced therapies, announced the formation of Dark Horse Consulting China and the appointment of Kang Liu as its inaugural hire. The new Shanghai…
Impact: Kang Liu's former employer; indirectly referenced, no direct impact from this event.
Aug 11, 2026 · 7 articles
Business
Impact: ADMA Biologics is the licensor of Whitehawk's existing ADC assets, but is not directly involved in this collaboration.
Jul 07, 2026 · 7 articles
Business
Bicara Therapeutics, an AI-driven drug discovery company based in Chengdu, China, announced the successful closing of an oversubscribed Series A financing round, raising nearly $30 million. The round was co-led by Legend Holdings and Shanghai…
Impact: ADMA Biologics is mentioned as a portfolio company of Legend Holdings, showing the investor's focus but not directly affected.
Jul 20, 2026 · 6 articles
100
Berger Montague filed class action ADMA BiologicsADMA Biologics Securities...
93
ADMA Biologics issued misleading informationADMA Biologics Securities...
90
ADMA Biologics concealed channel stuffingADMA Biologics Securities...
90
ADMA Biologics issued misleading statementsADMA Biologics Securities...
90
Culper Research published report ADMA BiologicsADMA Biologics Securities...
90
Bleichmar Fonti & Auld LLP announced investigation ADMA BiologicsADMA Biologics Securities...
90
Culper Research published report ADMA BiologicsADMA Biologics Securities...
90
Robbins Geller Rudman & Dowd LLP announced class action ADMA BiologicsADMA Biologics Securities...
85
ADMA Biologics certified controls effectiveADMA Biologics Securities...
85
ADMA Biologics omitted related party sales Genesis BioPharma ServicesADMA Biologics Securities...
75
Cantor Fitzgerald downgraded stock rating ADMA BiologicsADMA Biologics Securities...
71
Cantor Fitzgerald downgraded ADMA BiologicsADMA Biologics Securities...
70
ADMA Biologics lost CFO abruptlyADMA Biologics Securities...
70
Kahn Swick & Foti notified investors of lawsuit ADMA BiologicsADMA Biologics Securities...
70
Bronstein, Gewirtz & Grossman, LLC filed class action lawsuit ADMA BiologicsADMA Biologics Securities...
70
Faruqi & Faruqi filed class action ADMA BiologicsADMA Biologics Securities...
70
Levi & Korsinsky filed securities class action ADMA BiologicsADMA Biologics Securities...
70
Hagens Berman filed class action ADMA BiologicsADMA Biologics Securities...
65
Rosen Law Firm announced investigation ADMA BiologicsADMA Biologics Securities...
60
ADMA Biologics issued rebuttal Culper ResearchADMA Biologics Securities...
60
The Schall Law Firm reminded investors of lawsuit ADMA BiologicsADMA Biologics Securities...
60
Glancy Prongay & Murray filed class action lawsuit ADMA BiologicsADMA Biologics Securities...
60
DJS Law Group filed class action ADMA BiologicsADMA Biologics Securities...
60
The Law Offices of Frank R. Cruz announced opportunity to lead lawsuit ADMA BiologicsADMA Biologics Securities...
60
Schall Brown & Schwartz LLP filed class action ADMA BiologicsADMA Biologics Securities...
Culper Research
target
↔
ADMA Biologics
ADMA Biologics is the target of an activist short campaign by Culper Research, f
Culper Research
activist
↔
ADMA Biologics
Culper Research acts as an activist short seller against ADMA Biologics, publish
ERGEN INTELLIGENCE
Track ADMA Biologics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard